SCHEMBL2335176

SCHEMBL2335176

O=S(=O)(c1ccc(Cl)cc1)N(CCO)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.55
USP2 O75604 1/20 0.54
BACE1 P56817 1/20 0.53
NPSR1 Q6W5P4 2/20 0.51
PSEN1 P49768 8/20 0.50
PSEN2 P49810 8/20 0.50
APH1B Q8WW43 8/20 0.50
NCSTN Q92542 8/20 0.50
APH1A Q96BI3 8/20 0.50
PSENEN Q9NZ42 8/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
MAPK1 P28482 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20404429 0.81 PDE6D (0.53) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL2334987 0.79 SLC6A9 (0.51) SLC6A9USP2BACE1NPSR1PSEN1
SCHEMBL20404416 0.77 PDE6D (0.53) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL28161374 0.77 ALDH1A1 (0.54) USP2BACE1NPSR1PSEN1PSEN2
SCHEMBL2336654 0.77 POLB (0.54) SLC6A9USP2BACE1PSEN1PSEN2
SCHEMBL20387919 0.77 PDE6D (0.52) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL2338052 0.76 BACE1 (0.62) SLC6A9USP2BACE1NPSR1PSEN1
SCHEMBL14842203 0.76 MEN1 (0.79) USP2NPSR1PSEN1PSEN2APH1B
SCHEMBL20379478 0.75 PSEN1 (0.58) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL2335331 0.74 PSEN1 (0.53) SLC6A9PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP claimed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US claimed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
EP-1723102-A2 N-SUBSTITUTED BENZENE SULFONAMIDES Elan Pharmaceuticals, Inc. (US) 2006-11-22 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed
WO-2005090296-A2 N-SUBSTITUTED BENZENE SULFONAMIDES ELAN PHARMACEUTICALS, INC. (US) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE SLC6A9 3875/4885USP2 2822/4885BACE1 4/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE SLC6A9 3875/4885USP2 2822/4885BACE1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.